Investments
95Portfolio Exits
20Funds
5Partners & Customers
1About Borealis Ventures
Borealis Ventures partners closely with exceptional entrepreneurs to build market-defining companies. Its focus is on the opportunities to transform healthcare through new therapies, digital innovation, and other technologies.
Borealis Ventures Headquarter Location
10 Allen St., Upper Level
Hanover, New Hampshire, 03755,
United States
603.643.1500
Expert Collections containing Borealis Ventures
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Find Borealis Ventures in 1 Expert Collection, including Travel Technology (Travel Tech).
Travel Technology (Travel Tech)
39 items
Tech-enabled companies offering services and products focused on tourism. This collection includes booking services, search platforms, on-demand travel and recommendation sites, among others.
Latest Borealis Ventures News
Nov 16, 2021
Series B Proceeds Will Advance Ankyra’s lead molecule into the Clinic while Expanding Ankyra’s Tumor-Localized Immuno-Oncology Pipeline New Investors include Borealis Ventures, Fidelity Management & Research Company LLC, GV, Sands Capital Ventures, and Spring Mountain Capital and Existing Investors Polaris Partners and Mithril Capital Newly appointed Chief Medical Officer, Dr. Howard L. Kaufman, will lead clinical development November 12, 2021 08:00 AM Eastern Standard Time BOSTON--( BUSINESS WIRE )--Ankyra Therapeutics, a company developing cancer therapies based on tumor localized immune potentiating agents that boost anti-tumor immune responses, today announced the closing of a $45 million Series B financing. Proceeds from the financing will be used to progress Ankyra’s lead molecule, ANK-101 through Investigational New Drug (IND) enabling studies and into Phase 1 clinical trials, as well as advance additional cytokine programs. Several new investors including Borealis Ventures, Fidelity Management & Research Company LLC, GV, Sands Capital Ventures, and Spring Mountain Capital joined existing investors Polaris Partners and Mithril Capital. In connection with the closing of the financing, Phil Ferneau of Borealis Ventures will join the Ankyra Therapeutics Board of Directors. Ankyra Therapeutics has developed a highly differentiated technology platform that significantly expands the therapeutic window of immune-modulating oncology drugs by forming an extended drug depot following intratumoral administration. The company is rapidly progressing its lead molecule into clinical studies. “We are fortunate to have the support of investors who share our vision of developing tumor-localized cytokines and other immune therapies to treat cancer with enhanced efficacy and safety,” said Tillman Gerngross, Co-founder, and Executive Chairman of Ankyra Therapeutics. “This is an important moment for the company as we work to bring our first development program through IND and into Phase 1 clinical trials, and we are excited to bring Howard Kaufman, and his proven track record of successful clinical development, to the Ankyra team.” Dr. Kaufman has been a leading authority on tumor immunotherapy and oncolytic viruses for the treatment of melanoma. He led the first successful phase III trial of an intratumoral agent resulting in FDA approval for the treatment of melanoma. He served as president of the Society for Immunotherapy of Cancer (SITC) from 2014-2016. Prior to joining Ankyra, Dr. Kaufman was Head of Research and Development at Immuneering Corporation. Dr. Kaufman also served as chief medical officer at Replimune Group, Inc., where he oversaw the strategic development of the company’s pipeline. “Systemic treatment with cytokines and other immune agonists has been limited by broad immune activation and systemic toxicity. Intratumoral administration can improve the therapeutic window of immune activating drugs, but the approach has been limited by rapid clearance from the tumor microenvironment. There is a significant need for approaches that improve the therapeutic window and reduce the frequency of dosing. Ankyra’s approach is a true platform that can extend drug bioavailabity and enhance anti-tumor immune responses, while avoiding systemic adverse events. We look forward to extending our preclinical observations into cancer patients in our upcoming Phase 1 clinical trial,” stated Howard Kaufman, Chief Medical Officer of Ankyra. About Ankyra Therapeutics Ankyra Therapeutics is a biotechnology company that has developed a highly differentiated technology platform that expands the therapeutic window of cytokine drugs by forming a stable depot in the tumor after local administration leading to prolonged immune activation and potent local and systemic immunity with reduced systemic toxicity. Ankyra was founded in 2019 and is headquartered in Boston, Massachusetts. For more information, please visit www.ankyratx.com Contacts
Borealis Ventures Investments
95 Investments
Borealis Ventures has made 95 investments. Their latest investment was in Amagma Therapeutics as part of their Unattributed VC on June 6, 2022.
Borealis Ventures Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
6/1/2022 | Unattributed VC | Amagma Therapeutics | $2.28M | Yes | 1 | |
1/20/2022 | Series B | Blue Rabbit Ventures | $13.64M | Yes | 1 | |
9/8/2021 | Series B | Ankyra Therapeutics | $45M | Yes | 2 | |
7/20/2021 | Series B | |||||
2/18/2021 | Series C |
Date | 6/1/2022 | 1/20/2022 | 9/8/2021 | 7/20/2021 | 2/18/2021 |
---|---|---|---|---|---|
Round | Unattributed VC | Series B | Series B | Series B | Series C |
Company | Amagma Therapeutics | Blue Rabbit Ventures | Ankyra Therapeutics | ||
Amount | $2.28M | $13.64M | $45M | ||
New? | Yes | Yes | Yes | ||
Co-Investors | |||||
Sources | 1 | 1 | 2 |
Borealis Ventures Portfolio Exits
20 Portfolio Exits
Borealis Ventures has 20 portfolio exits. Their latest portfolio exit was Avitide on September 16, 2021.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
9/16/2021 | Acquired | 4 | |||
7/21/2021 | Acquired | 8 | |||
6/23/2020 | Reverse Merger | 1 | |||
Date | 9/16/2021 | 7/21/2021 | 6/23/2020 | ||
---|---|---|---|---|---|
Exit | Acquired | Acquired | Reverse Merger | ||
Companies | |||||
Valuation | |||||
Acquirer | |||||
Sources | 4 | 8 | 1 |
Borealis Ventures Acquisitions
2 Acquisitions
Borealis Ventures acquired 2 companies. Their latest acquisition was Vico Software on March 23, 2007.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
---|---|---|---|---|---|---|
3/23/2007 | Series B | $3.6M | Acquired | |||
6/30/2004 | Private Equity |
Date | 3/23/2007 | 6/30/2004 |
---|---|---|
Investment Stage | Series B | Private Equity |
Companies | ||
Valuation | ||
Total Funding | $3.6M | |
Note | Acquired | |
Sources |
Borealis Ventures Fund History
5 Fund Histories
Borealis Ventures has 5 funds, including Vox Health Fund.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
---|---|---|---|---|---|
1/27/2020 | Vox Health Fund | $12.05M | 1 | ||
9/6/2018 | Built Environment Innovation Fund LP | ||||
12/5/2012 | Borealis Granite Fund | ||||
5/30/2003 | The Borealis Fund LP | ||||
Borealis Ventures II |
Closing Date | 1/27/2020 | 9/6/2018 | 12/5/2012 | 5/30/2003 | |
---|---|---|---|---|---|
Fund | Vox Health Fund | Built Environment Innovation Fund LP | Borealis Granite Fund | The Borealis Fund LP | Borealis Ventures II |
Fund Type | |||||
Status | |||||
Amount | $12.05M | ||||
Sources | 1 |
Borealis Ventures Partners & Customers
1 Partners and customers
Borealis Ventures has 1 strategic partners and customers. Borealis Ventures recently partnered with Johnson & Johnson, and Dartmouth College on November 11, 2017.
Date | Type | Business Partner | Country | News Snippet | Sources |
---|---|---|---|---|---|
11/27/2017 | Partner | United States | News from Borealis Ventures Motorola Invests in Handmark. (acquired by AIG Alteris Health Partners). `` It will be an active partnership with Johnson & Johnson and Borealis Ventures . | 1 |
Date | 11/27/2017 |
---|---|
Type | Partner |
Business Partner | |
Country | United States |
News Snippet | News from Borealis Ventures Motorola Invests in Handmark. (acquired by AIG Alteris Health Partners). `` It will be an active partnership with Johnson & Johnson and Borealis Ventures . |
Sources | 1 |
Borealis Ventures Team
3 Team Members
Borealis Ventures has 3 team members, including current Founder, Managing Partner, Phil Ferneau.
Name | Work History | Title | Status |
---|---|---|---|
Jesse Devitte | Autodesk, Softdesk, and White House | Founder | Current |
Phil Ferneau | Founder, Managing Partner | Current | |
Matt Rightmire | Efficient Frontier, and Yahoo! | Managing Director | Current |
Name | Jesse Devitte | Phil Ferneau | Matt Rightmire |
---|---|---|---|
Work History | Autodesk, Softdesk, and White House | Efficient Frontier, and Yahoo! | |
Title | Founder | Founder, Managing Partner | Managing Director |
Status | Current | Current | Current |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.